ClinicalTrials.gg
CompletedNCT01298310Updated May 22, 2012

A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

An Early Phase 1 interventional study of Xylocaine and Xylocaine in Morton's Neuroma, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-22.

Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To characterize the phenotype in patients with Morton's neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Read the detailed description

A randomised, double-blind, placebo-controlled, three-way cross-over single center study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

02

Conditions studied

  • Morton's Neuroma

Browse trials for

Keywords

  • Morton's neuroma, QST measurements
03

In context

Morton Neuroma

25 studies on the registry are indexed under Morton Neuroma; 3 are open to participants now.

This study's enrollment of 27 is below the median of 60 across 21 interventional studies indexed under Morton Neuroma.

Browse Morton Neuroma studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a clinical diagnosis of Morton's neuroma with symptoms of at least 3 months duration in one foot (affected foot)
  • Visual analogue scale (VAS) pain-score of = 40 mm in the painful foot at daily activities during the previous week (visit 1)

Exclusion criteria

Exclusion Criteria:

  • Allergy to lidocaine
  • Scars or other dermal conditions on the feet that may interfere with study procedures
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    Xylocaine_1mg

    1 injection of Xylocaine (1 mg/mL)

    Drug: Xylocaine

  • Active comparator
    Xylocaine_10mg

    1 injection of Xylocaine (10 mg/mL)

    Drug: Xylocaine

  • Placebo comparator
    Placebo

    1 injection of placebo

    Drug: Placebo

Interventions

  • 1 mg/mL solution for injection

  • 10 mg/mL solution for injection

  • DrugPlacebo

    solution for injection

06

What researchers measure

Primary outcomes

  1. The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: Before and after drug injection at Day 1

  2. The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: Before and after drug injection at Day 14 (+/-9).

  3. The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: Before and after drug injection at Day 28 (+/-18).

  4. The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: After drug injection at Day 1.

  5. The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: After drug injection at Day 14 (+/-9).

  6. The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)

    Time frame: After drug injection at Day 28 (+/-18).

Secondary outcomes

  1. Frequency/severity of adverse events

    Time frame: Day 1

  2. Frequency/severity of adverse events

    Time frame: Day 14 (+/-9)

  3. Frequency/severity of adverse events

    Time frame: Day 28 (+/-18)

  4. Frequency/severity of adverse events

    Time frame: Day 43 (+/-32)

07

Study locations

1 site
  • Research Site
    Stockholm, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2011
First posted
Feb 17, 2011
Start
Feb 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
May 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01298310
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 17, 2011
Start date
Feb 2011
Primary completion
May 2012
Completion
May 2012
Last update
May 22, 2012

Study contacts

Bror Jonzon, MD, PhD
study director · AstraZeneca R&D Södertälje, Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion